Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction.
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
medline:
16
10
2023
pubmed:
16
10
2023
entrez:
16
10
2023
Statut:
epublish
Résumé
Senescent cells accumulate in organisms over time because of tissue damage and impaired immune surveillance and contribute to age-related tissue decline
Identifiants
pubmed: 37841853
doi: 10.21203/rs.3.rs-3385749/v1
pmc: PMC10571605
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R01 CA188134
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA190092
Pays : United States
Organisme : NIH HHS
ID : DP5 OD033055
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA224013
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA045508
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG065396
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA229699
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG082800
Pays : United States
Organisme : NIH HHS
ID : S10 OD028632
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA210240
Pays : United States
Déclaration de conflit d'intérêts
Competing Interests C.A., J.F., M.S. and S.W.L. are listed as the inventors of several patent applications (62/800,188; 63/174,277; 63/209,941; 63/209,940; 63/209,915; 63/209,924; 17/426,728; 3,128,368; 20748891.7; 2020216486) related to senolytic CAR T cells. C.A., M.S. and S.W.L. are advisors for Fate Therapeutics. S.W.L. also has provided consultancy for and had equity in Oric Pharmaceuticals, Blueprint Medicines, Mirimus Inc, Senecea Therapeutics, Faeth Therapeutics, and PMV Pharmaceuticals. D.A.T. is a member of the Scientific Advisory Board and receives stock options from Leap Therapeutics, Dunad Therapeutics, Cygnal Therapeutics and Mestag Therapeutics outside the submitted work. D.A.T. is scientific co-founder of Mestag Therapeutics. D.A.T. has received research grant support from Fibrogen, Mestag, and ONO Therapeutics. D.A.T. receives grant funding from the Lustgarten Foundation, the NIH, and the Thompson Foundation. None of this work is related to the publication. No other disclosures were reported. R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Zentalis, Ajax, Auron, Prelude, C4 Therapeutics and Isoplexis. R.L.L. receives research support from Ajax, Zentalis and Abbvie and has consulted for Incyte, Janssen and Astra Zeneca and has received honoraria from Astra Zeneca for invited lectures. L.W.J owns stock in Pacyclex, Inc., and Illuminosonics, Inc. M.S. holds other unrelated patents on CAR technologies. S.W.L is an advisor for and has equity in the following biotechnology companies: ORIC Pharmaceuticals, Faeth Therapeutics, Blueprint Medicines, Geras Bio, Mirimus Inc., PMV Pharmaceuticals and Constellation Pharmaceuticals.
Références
Sci Adv. 2022 Oct 7;8(40):eabo3932
pubmed: 36197983
Cell. 2016 Apr 21;165(3):535-50
pubmed: 27104977
Sci Rep. 2022 May 18;12(1):8328
pubmed: 35585103
Nat Med. 2019 Jan;25(1):82-88
pubmed: 30559421
Elife. 2015 Dec 19;4:e12997
pubmed: 26687007
J Vis Exp. 2013 Aug 02;(78):
pubmed: 23963434
Science. 2016 Oct 28;354(6311):472-477
pubmed: 27789842
Nat Aging. 2021 Dec;1(12):1117-1126
pubmed: 37117524
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Nat Protoc. 2009;4(12):1798-806
pubmed: 20010931
Nat Rev Cancer. 2015 Jul;15(7):397-408
pubmed: 26105537
Elife. 2020 Nov 19;9:
pubmed: 33210602
Cell. 2013 Jun 6;153(6):1194-217
pubmed: 23746838
Nature. 2022 Feb;602(7897):503-509
pubmed: 35110735
J Gerontol A Biol Sci Med Sci. 2021 Jan 18;76(2):318-327
pubmed: 32766674
Cell Metab. 2019 Jul 2;30(1):129-142.e4
pubmed: 31155496
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
Science. 2018 Dec 21;362(6421):1416-1422
pubmed: 30573629
Obesity (Silver Spring). 2007 Apr;15(4):798-808
pubmed: 17426312
Nature. 2011 Nov 02;479(7372):232-6
pubmed: 22048312
Nat Rev Cardiol. 2018 Sep;15(9):505-522
pubmed: 30065258
Nat Med. 2003 Mar;9(3):279-86
pubmed: 12579196
STAR Protoc. 2020 Oct 20;1(3):100144
pubmed: 33377038
Cell Death Dis. 2019 Mar 13;10(3):249
pubmed: 30867412
J Vis Exp. 2013 May 22;(75):e50707
pubmed: 23728515
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
pubmed: 20027185
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Nat Med. 2015 Dec;21(12):1424-35
pubmed: 26646499
Geroscience. 2019 Aug;41(4):455-465
pubmed: 31468322
Cancer Cell. 2023 Jul 10;41(7):1261-1275.e6
pubmed: 37267954
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Nature. 2020 Jul;583(7817):590-595
pubmed: 32669714
Nat Med. 2018 Aug;24(8):1246-1256
pubmed: 29988130
Nature. 2020 Jul;583(7814):127-132
pubmed: 32555459
Cell. 2007 Jul 27;130(2):223-33
pubmed: 17662938
Sci Transl Med. 2023 Aug 16;15(709):eadd1951
pubmed: 37585504
Nat Commun. 2022 Aug 16;13(1):4827
pubmed: 35974106
Nat Genet. 2004 Jul;36(7):744-9
pubmed: 15208629
PLoS One. 2013 Apr 09;8(4):e61338
pubmed: 23585892
Nature. 2018 Oct;562(7728):578-582
pubmed: 30232451
Front Pharmacol. 2014 Oct 28;5:235
pubmed: 25389405
Nature. 2017 May 24;545(7655):423-431
pubmed: 28541315
Nat Protoc. 2015 Feb;10(2):305-15
pubmed: 25612230
FEBS J. 2023 Mar;290(5):1362-1383
pubmed: 35015337
Cancer Discov. 2016 Jun;6(6):612-29
pubmed: 27099234
Nat Commun. 2018 Dec 21;9(1):5435
pubmed: 30575733
EMBO Mol Med. 2018 Sep;10(9):
pubmed: 30012580
Nature. 2016 Feb 11;530(7589):184-9
pubmed: 26840489
PLoS One. 2015 May 29;10(5):e0128274
pubmed: 26023930
Cancer Cell. 2023 Jul 10;41(7):1242-1260.e6
pubmed: 37267953